A new oral GLP-1 pill called elecoglipron significantly lowered blood sugar and drove substantial weight loss in adults with type 2 diabetes, according to results from the SOLSTICE phase 2b trial presented at the American Diabetes Association's Scientific Sessions and published simultaneously in The Lancet. The AstraZeneca-sponsored trial enrolled 406 patients across nine countries and tested a non-peptide oral GLP-1 receptor agonist designed to bypass the dosing...